SECOND SIGHT MEDICAL PRODUCT (EYES) Stock Price, Forecast & Analysis
USA - NASDAQ:EYES - US81362J3086 - Common Stock
EYES Key Statistics, Chart & Performance
The current stock price of EYES is 4.14 USD. In the past month the price decreased by -23.33%. In the past year, price decreased by -63.1%.
EYES Latest News, Press Relases and Analysis
EYES Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.32 | 219.92B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.04 | 200.75B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.91 | 148.20B | ||
| SYK | STRYKER CORP | 27.03 | 136.11B | ||
| IDXX | IDEXX LABORATORIES INC | 56.18 | 56.68B | ||
| BDX | BECTON DICKINSON AND CO | 12.33 | 50.97B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.45 | 48.96B | ||
| RMD | RESMED INC | 25.4 | 36.70B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.92 | 33.35B | ||
| PODD | INSULET CORP | 75.61 | 22.51B | ||
| DXCM | DEXCOM INC | 29.57 | 21.57B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.53B |
Related stock screener links
About EYES
Company Profile
Second Sight Medical Products Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Sylmar, California and currently employs 15 full-time employees. The company went IPO on 2014-11-19. Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The firm manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). The company is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.
Company Info
SECOND SIGHT MEDICAL PRODUCT
12744 San Fernando Road, Bldg. 3
Sylmar CALIFORNIA 91342 US
CEO: Matthew Pfeffer
Employees: 15
Phone: 18188335000.0
SECOND SIGHT MEDICAL PRODUCT / EYES FAQ
Can you describe the business of SECOND SIGHT MEDICAL PRODUCT?
Second Sight Medical Products Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Sylmar, California and currently employs 15 full-time employees. The company went IPO on 2014-11-19. Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The firm manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). The company is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.
What is the stock price of SECOND SIGHT MEDICAL PRODUCT today?
The current stock price of EYES is 4.14 USD. The price decreased by -5.05% in the last trading session.
Does EYES stock pay dividends?
EYES does not pay a dividend.
How is the ChartMill rating for SECOND SIGHT MEDICAL PRODUCT?
EYES has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the expected growth for EYES stock?
The Revenue of SECOND SIGHT MEDICAL PRODUCT (EYES) is expected to grow by 35.73% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
EYES Technical Analysis
EYES Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to EYES. EYES has a great financial health rating, but its profitability evaluates not so good.
EYES Financial Highlights
Over the last trailing twelve months EYES reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS decreased by -42.18% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.82% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
EYES Forecast & Estimates
For the next year, analysts expect an EPS growth of 96.18% and a revenue growth 35.73% for EYES